Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of medications that can be picked up at a local pharmacy.

The FDA authorized the third monoclonal antibody treatment. Here's why Vir and GSK say the U.S. still needs COVID-19 therapies

GlaxoSmithKline and Vir Biotechnology won FDA authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. The post The Surprising Move Vir Stock Made After Winning Covid Drug Authorization appeared first on Investor's Business Daily.

The Surprising Move Vir Stock Made After Winning Covid Drug Authorization

Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug Administration (FDA). The federal agency's approval for Sotrovimab (VIR-7831) that the biotech firm developed in collaboration with GlaxoSmithKline applies to pediatric patients and high-risk […] The post Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment appeared first on Invezz.

Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment

Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate COVID-19 in people aged 12 years and older. The EUA comes after Vir's antibody proved 85% effective at preventing hospitalization in high-risk, newly diagnosed COVID-19 patients.

Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug

GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk of severe illness, including hospitalization or death. Vir Chief Executive George Scangos said an interim analysis of data produced in a laboratory found the antibody treatment showed an 85% reduction in all-cause hospitalizations or death and is effective against all known variants of concern, including the emerging variant from India.

GlaxoSmithKline and Vir win FDA emergency authorization for COVID antibody treatment in adults and children

GlaxoSmithKline PLC (LON:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) have announced the US Food and Drug Administration (FDA) granted emergency use authorisation for their COVID-19 treatment. Sotrovimab will be used to help adults and paediatric patients aged over 12 with mild-to-moderate symptoms, and who are at high risk for progression to severe COVID-19, including hospitalisation or death.

GlaxoSmithKline receives US emergency authorisation for COVID-19 treatment

– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk  adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial –

GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

The European Medicines Agency's advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-19 treatment, sotrovimab, can be used. The opinion covers confirmed COVID-19 in adults and adolescents who don't require supplemental oxygen therapy and are at risk of progressing to severe COVID-19.

GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion

– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –

CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's Sotrovimab For the Early Treatment of COVID-19

EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's Sotrovimab For the Early Treatment of COVID-19

– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021

VIR did well with the prophylaxis studies but failed to impress with the hospitalisation data. Upcoming EUA and EMA reviews may be catalytic.

Vir Biotechnology: Not Nearly Enough

VBI Vaccines

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment of chronic HBV infection. The open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant.

Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study

DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chr

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Vir is developing treatments in billion-dollar markets.

Could Vir Biotechnology Be a Millionaire Maker Stock?

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19 GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19

GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19

Eli Lilly

One of the three clearly has the most upside potential.

Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –

Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells

Sorrento Therapeutics Inc

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says.

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th at 8:45 am PT / 11:45 am ET.

News for Vir Biotechnology Stock (VIR)